DSM Biologics to Acquire Rhobust Technology from Upfront Chromatography
DSM Biologics (Parsippany, NJ), a business unit of DSM Pharmaceutical products, has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Upfront Chromatography A/S (Copenhagen, Denmark) for pharmaceutical and other applications.
DSM Biologics (Parsippany, NJ), a business unit of DSM Pharmaceutical products, has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Upfront Chromatography A/S (Copenhagen, Denmark) for pharmaceutical and other applications.
DSM Biologics will gain all rights for the commercialization of the Rhobust technology in various fields, including the pharmaceutical industry. DSM Biologics will continue to support all existing clients for this technology. Financial details were not disclosed.
Upfront’s Rhobust technology consists of cross-linked Tungsten Carbide—agarose beads to increase the density of the particles. This increased density leads to stable expanded bed adsorption chromatography. Compared to a conventional harvest approach, the number of unit operations is reduced. The cells are separated in one step while capturing the protein or antibody of interest. In the expanded bed adsorption chromatography (EBA) the cell suspension passes through the column and the product is adsorbed either on Protein A or on mixed-mode ligand beads. This leads to less handling and shorter process times.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
